• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

US Registry Analysis Finds Seven Week Average Interval for Avacincaptad Pegol

by
November 17, 2026
in Health
Reading Time: 6 mins read
0
US Registry Analysis Finds Seven Week Average Interval for Avacincaptad Pegol

US Registry Analysis Finds Seven Week Average Interval for Avacincaptad Pegol

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In routine clinical practice across the United States during the first year after regulatory approval, patients receiving avacincaptad pegol for geographic atrophy were treated at an average interval of seven weeks, extending beyond the monthly schedule evaluated in pivotal trials. This finding emerges from an observational study analyzing secondary electronic health record data from the American Academy of Ophthalmology Intelligent Research in Sight Registry, known as the IRIS Registry. The retrospective investigation evaluated 10,181 patients representing 13,391 eligible patient-eyes who initiated therapy between September 1, 2023, and August 31, 2024. Avacincaptad pegol, a pegylated RNA aptamer targeting complement component 5, was approved by the Food and Drug Administration in August 2023 as a two-milligram intravitreal injection to slow geographic atrophy lesion growth secondary to age-related macular degeneration. Across a mean follow-up of 24.6 weeks, eyes received an average of 3.7 injections, offering the first large-scale empirical analysis of how community ophthalmologists administer the therapy in everyday practice.

Geographic atrophy represents an advanced manifestation of age-related macular degeneration that causes irreversible vision loss, progressive retinal tissue destruction, and substantial declines in patient independence. For decades, clinicians lacked approved medical therapies capable of slowing disease progression. That landscape shifted in 2023 when the Food and Drug Administration approved two complement-inhibiting agents: pegcetacoplan and avacincaptad pegol. Complement component 5 functions as a critical terminal regulatory protein that drives inflammation and cellular death in the pathogenesis of geographic atrophy. By binding to complement component 5 and suppressing its activity, avacincaptad pegol slows lesion expansion, as demonstrated in the randomized GATHER1 and GATHER2 clinical trials. While randomized trials provide rigorous efficacy benchmarks, routine practice involves broader and more heterogeneous patient groups. To evaluate community utilization, investigators examined the IRIS Registry, which compiles deidentified records from nearly 3,000 practices and over 14,000 eye clinicians nationwide, capturing longitudinal health data from approximately 86 million individual patients as of October 2025.

To construct the cohort, researchers queried the IRIS Registry for individuals aged 50 years or older with a verified diagnosis of geographic atrophy within 36 months before their first injection. Diagnoses were identified using specific International Classification of Diseases, Tenth Revision, Clinical Modification codes or clinical notes. The index date was defined as a patient’s initial two-milligram avacincaptad pegol injection between September 1, 2023, and August 31, 2024. Investigators retrieved up to three years of pre-index patient records to characterize baseline demographics, ocular disease histories, and clinical interventions. To qualify, patients required documented treatment laterality and at least 30 days of post-index follow-up. Patients with prior avacincaptad pegol exposure before the index period were excluded. Out of 12,019 diagnosed patients representing 15,892 patient-eyes initiating treatment, minor exclusions occurred based on age, and roughly 15 percent were excluded due to insufficient follow-up, yielding a final cohort of 10,181 patients and 13,391 eyes.

Demographic analyses showed that patients initiating real-world avacincaptad pegol therapy were predominantly elderly and female. The mean cohort age was 81.7 years, with 66.2 percent aged 80 years or older. Female patients constituted 65.6 percent of participants, while male patients comprised 34.4 percent. Regarding racial and ethnic composition, 76.1 percent of patients were white, and 72.3 percent were not Hispanic or Latino. Health insurance data revealed that 80 percent of patients held Medicare Fee for Service coverage, while approximately 10 percent had commercial health insurance. Although bilateral geographic atrophy was documented in 87.1 percent of patients, corresponding to 8,865 individuals, clinicians administered avacincaptad pegol in only one eye for 68.5 percent of patients, or 6,971 individuals. Only 31.5 percent received bilateral injections. While treatment laterality rationales were unrecorded in registry data, expert consensus guidelines note that single-eye versus bilateral decisions depend on patient symptoms, visual acuity, age, fellow-eye status, and comorbid ocular conditions.

Baseline clinical evaluations showed that 62.0 percent of enrolled patients had no additional diagnosed ocular comorbidities beyond geographic atrophy before their index injection. Among those with documented retinal conditions, the most prevalent baseline diagnoses were neovascular age-related macular degeneration in 34.3 percent, or 3,488 patients, and choroidal neovascularization in 28.2 percent, or 2,867 patients. The authors noted that these categories relied on separate administrative billing codes that overlap in routine practice and often reflect coinciding manifestations of macular neovascularization rather than independent entities. For nonretinal conditions, 60.9 percent of patients had no prior diagnoses; however, cataracts were present at baseline in 24.2 percent, and glaucoma or ocular hypertension was documented in 19.8 percent. Baseline safety screening showed that 95.4 percent of patients had no key adverse-event-qualifying condition in the 180 days before treatment. In addition, 78.3 percent had not received antivascular endothelial growth factor injections during that pre-index period.

Across the study cohort, the mean observational follow-up duration was 24.6 weeks with a standard deviation of 12.0 weeks. Patient-eyes received a mean of 3.7 injections of avacincaptad pegol, with a standard deviation of 2.3 injections. Among eyes receiving at least two injections spaced no more than 120 days apart, the average injection interval was 7.0 weeks with a standard deviation of 2.1 weeks. Only 11.9 percent of patient-eyes received a single injection during follow-up. In total, 47.9 percent of patient-eyes received injections at intervals between five and eight weeks, and 15.4 percent were treated at intervals under five weeks. Time from geographic atrophy diagnosis to first treatment varied widely: 41.1 percent of patient-eyes received their initial injection within one year of diagnosis, 17.9 percent between one and two years, 17.7 percent between two and three years, and 23.4 percent initiated treatment three or more years after diagnosis.

Treatment persistence was relatively stable over the early adoption period, with therapy discontinuation documented in 8.7 percent of patients. Discontinuation was defined as an interval exceeding 120 days between consecutive avacincaptad pegol injections or the initiation of pegcetacoplan in the eligible patient-eye. Switching to pegcetacoplan occurred in 3.3 percent of patients. Furthermore, concomitant antivascular endothelial growth factor therapy was administered in 22.7 percent of patient-eyes during follow-up to address coexisting neovascular disease. Because the observation period ended on September 30, 2024, approximately 78 percent of patients were censored at study closure before reaching discontinuation endpoints. In addition, 13.2 percent of patients were lost to follow-up, defined by an absence of registry records for at least 120 days after their final injection. These censoring figures reflect the early timeframe of the registry analysis and the relatively short follow-up available during the initial commercial rollout in routine clinical practice.

Safety monitoring focused on prespecified key adverse events newly recorded within a postinjection at-risk window spanning one to 30 days after each administration. To isolate incident postinjection complications, diagnosis codes recorded within 180 days before an injection were excluded from counting as new adverse events. Under this framework, 3.6 percent of patients and 2.9 percent of patient-eyes experienced at least one key adverse event, representing an overall rate of 102.9 events per 10,000 injections. The most frequent newly recorded conditions were neovascular age-related macular degeneration in 0.75 percent of eyes, or 100 eyes, and choroidal neovascularization in 0.72 percent of eyes, or 96 eyes. Cox proportional hazards regression models demonstrated that having an adverse condition before initiating avacincaptad pegol did not significantly predict postinjection adverse events, yielding an adjusted hazard ratio of 1.278, a 95 percent confidence interval of 0.658 to 2.484, and a p-value of 0.4693.

Severe vision loss linked to adverse events, defined as a loss of 30 or more Early Treatment Diabetic Retinopathy Study letters—equivalent to losing six visual acuity lines—was rare and was not observed with choroidal neovascularization, neovascular macular degeneration, cystoid macular degeneration, or retinal vascular occlusion among eyes with post-event measurements. Severe vision loss occurred primarily with endophthalmitis in 13 eyes or 0.10 percent, intraocular inflammation in four eyes or 0.03 percent, retinal detachment in two eyes or 0.01 percent, hypopyon in one eye or 0.01 percent, and ischemic optic neuropathy in one eye or 0.01 percent. Overall intraocular inflammation was documented in 19 patient-eyes across 18 patients, representing 0.14 percent of eyes. A pilot clinical note abstraction showed that one case of retinal vasculitis lacked angiographic confirmation, while three inflammatory events were linked to prior intermediate uveitis, recurrent uveitis, or optic neuropathy, illustrating documentation complexities in administrative registries.

The observed seven-week injection interval differs from the monthly regimen assessed in the first year of the pivotal GATHER trials, likely reflecting clinical decisions between doctors and patients to reduce treatment burden and clinic visits. In year two of the GATHER2 trial, every-other-month dosing demonstrated significant reductions in geographic atrophy lesion growth without new safety signals, providing clinical support for extended real-world intervals. The authors noted several limitations, including reliance on secondary electronic records with variable documentation, potential under-ascertainment of late-onset events beyond the 30-day window, lack of an untreated comparator group, and restriction to United States practices. Because roughly one-third had baseline neovascular disease and nearly a quarter received concomitant antivascular endothelial growth factor therapy, some eyes may have had macular atrophy associated with neovascular disease rather than pure geographic atrophy. As avacincaptad pegol received approvals in Japan and Australia in late 2025, extended registries will provide broader insight into global clinical practice.

Subject of Research: Real-world clinical adoption and treatment patterns of avacincaptad pegol for geographic atrophy

Article Title: Early Clinical Adoption and Treatment Patterns of Avacincaptad Pegol for Geographic Atrophy in the USA: An IRIS® Registry Analysis

Article References: Borkar, D., Toth, J., Balasubramanian, S., Stoelzel, M., Wolfram, J., & Shortridge, E. (2026). Early Clinical Adoption and Treatment Patterns of Avacincaptad Pegol for Geographic Atrophy in the USA: An IRIS® Registry Analysis. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-026-01522-x

Image Credits: AI Generated

DOI: 10.1007/s40123-026-01522-x

Keywords: geographic atrophy, avacincaptad pegol, IRIS Registry, age-related macular degeneration, retinal disease, intravitreal injections, complement component 5, choroidal neovascularization, neovascular AMD, intraocular inflammation, endophthalmitis, pegcetacoplan, visual acuity, treatment patterns, ophthalmology, real-world evidence, retinal vascular occlusion

News Source: Ophelia Keating. (November 17, 2026). US Registry Analysis Finds Seven Week Average Interval for Avacincaptad Pegol. Scienmag.

Tags: Age-related macular degenerationavacincaptad pegolChoroidal neovascularizationcomplement component 5endophthalmitisgeographic atrophyintraocular inflammationintravitreal injectionsIRIS registryNeovascular AMDOphthalmologypegcetacoplanReal-world evidenceretinal diseaseretinal vascular occlusiontreatment patternsvisual acuity
Share12Tweet7Share2ShareShareShare1

Related Posts

Somali Children Report Both Cognitive Benefits and Study Disruptions from Mobile Gaming

Somali Children Report Both Cognitive Benefits and Study Disruptions from Mobile Gaming

November 17, 2026
Stem Cell Exosomes Mitigate Brain Injury in Rat Cerebral Palsy Models

Stem Cell Exosomes Mitigate Brain Injury in Rat Cerebral Palsy Models

November 17, 2026

Meta-Analysis Finds AI Tools Benefit Students With Disabilities But Rigor Lacks

November 17, 2026

Saudi Hospital Study Finds Repeated Outpatient PPI Prescriptions Clustered in Chronic Illness

November 17, 2026

POPULAR NEWS

  • Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    29 shares
    Share 12 Tweet 7
  • Quality Improvement Project Raises Pre-Antibiotic Microbiological Analysis Rate to 79.2 Percent

    29 shares
    Share 12 Tweet 7
  • LLM-Driven Social Simulations Face Significant Epistemic Validity Challenges

    29 shares
    Share 12 Tweet 7
  • Veterinary Brucellosis Testing Requires Validated Decision Rules Across Animal Populations

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Somali Children Report Both Cognitive Benefits and Study Disruptions from Mobile Gaming

Stem Cell Exosomes Mitigate Brain Injury in Rat Cerebral Palsy Models

Meta-Analysis Finds AI Tools Benefit Students With Disabilities But Rigor Lacks

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.